CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 11/08/23

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Cyclacel Pharmaceuticals Inc. (CYCC) is expected to report $-0.38 for Q3 2023

BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Mond...

2023-10-18 11:22:58 ET More on Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Call Transcript Historical earnings data for Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% Dividend scorecard for Cyclacel Pharmaceutica...

2023-09-04 09:53:43 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals Inc. ( CYCC ) Q2 2023 Earnings Call Transcript Cyclacel Pharmaceuticals GAAP EPS of -$0.60 misses by $0.12 Cyclacel stock rises 16% as net loss narrows, income grows Cyclacel...

2023-08-09 21:42:12 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Conference Call Aug 9, 2023 4:30 PM ET Company Participants Grace Kim - Investor Relations Spiro Rombotis - President and Chief Executive Officer Mark Kirschbaum - Senior Vice President ...

2023-08-09 16:49:00 ET Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q2 GAAP EPS of -$0.44 beats by $0.06 . Revenue of $0.37M. For further details see: Cyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37M

- Key Catalysts ahead with Multiple Value Generating Readouts- - Expects to Release Phase 1/2 Data with Oral Fadraciclib - - Signals of Single-agent Efficacy with Oral Plogosertib - - Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGH...

BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wed...

2023-05-11 19:59:08 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu...